Skip to main
ALLR

Allarity Therapeutics (ALLR) Stock Forecast & Price Target

Allarity Therapeutics (ALLR) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Allarity Therapeutics Inc demonstrates a compelling investment opportunity due to its attractive current valuation, with an increased net present value (NPV) analysis indicating substantial upside potential. The company's lead candidate, stenoparib, offers promising clinical outcomes, particularly with new data revealing a median overall survival exceeding 25 months for patients with advanced recurrent ovarian cancer and limited treatment alternatives. Additionally, the integration of proprietary Drug Response Predictor (DRP) technology enhances patient selection, likely leading to improved clinical outcomes and supporting the company's growth trajectory in the precision medicine space.

Bears say

Allarity Therapeutics Inc. reported a net loss of $2.8 million, translating to an earnings per share (EPS) of $(0.19), which is slightly better than estimates but still reflects significant financial strain. The ongoing development of stenoparib is burdened by substantial risks, including potential failures in clinical trials, challenges in obtaining regulatory approvals, and issues related to market competition and reimbursement. Furthermore, liquidity and balance sheet risks pose additional concerns that may hinder the company's ability to sustain operations and achieve its growth objectives.

Allarity Therapeutics (ALLR) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Allarity Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Allarity Therapeutics (ALLR) Forecast

Analysts have given Allarity Therapeutics (ALLR) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Allarity Therapeutics (ALLR) has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Allarity Therapeutics (ALLR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.